Avenue Therapeutics: Clinical Pipeline Advances Drive Investor Focus

The clinical development pipeline at Avenue Therapeutics is progressing, with recent strategic moves placing several drug candidates in the spotlight. The company’s ability to navigate these programs through advanced trial phases is now a key consideration for investors.

AJ201 and Tramadol Programs Show Progress

A significant component of the company’s strategy is AJ201, an orally administered therapeutic candidate for spinal and bulbar muscular atrophy (SBMA), also referred to as Kennedy’s disease. Avenue recently completed the final patient visit in a Phase 1b/2a clinical study for this asset. The forthcoming data from this trial is viewed as a critical validation point for the program.

In a separate development track, Avenue is advancing an intravenous formulation of Tramadol. This candidate is designed for the management of acute postoperative pain under medical supervision. The timeline for this program remains contingent on achieving further regulatory milestones.

Should investors sell immediately? Or is it worth buying Avenue Therapeutics?

Strategic Licensing Agreement for ATX-04

Adding to its pipeline, Avenue Therapeutics secured an exclusive worldwide license for ATX-04 (Clenbuterol) from Duke University in late February. The company intends to move this compound directly into late-stage clinical development for the treatment of Pompe disease. This accelerated path is supported by existing human safety and efficacy data. The initial focus will be on a combination therapy approach with enzyme replacement treatment, while retaining the potential to expand into related indications.

Future Financial Catalysts from Axsome Deal

Beyond its internal pipeline, Avenue’s financial position could be bolstered by potential payments from a prior transaction. In November 2025, Axsome Therapeutics acquired the majority-owned subsidiary Baergic Bio, thereby obtaining the rights to BAER-101. As part of this agreement, Avenue Therapeutics is eligible to receive future milestone payments and royalties upon the achievement of specified development and commercial targets.

The immediate focus for the coming months will be the initiation of the registration program for ATX-04 and the analysis of data from the AJ201 study. These outcomes are expected to be pivotal in determining the pace at which Avenue can clear subsequent regulatory hurdles.